Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia. Ojjaara is a…

Read MoreOjjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, for adults with pulmonary arterial hypertension (PAH) (WHO Group 1) at the…

Read MoreMerck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect…

Read MoreEuropean Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

CVS Health announces additional responsibilities for executive leadership team members

 CVS Health® Corporation (NYSE: CVS) today announced additional responsibilities for several members of the company’s executive leadership team, effective immediately: “At a time when we are accelerating our strategy to deliver superior health experiences for consumers, we are advancing leaders who…

Read MoreCVS Health announces additional responsibilities for executive leadership team members

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months…

Read MorePfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world’s leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product. Monrol,…

Read MoreMonrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

DirectMed Parts & Service Announces Partnership and Investment in Technical Prospects

DirectMed Parts & Service (“DirectMed”), a leading medical imaging parts, systems, and service company, and portfolio company of NMS Capital (“NMS”), announced today that it has acquired Technical Prospects, LLC (“Technical Prospects” or the “Company”), a leading provider of parts,…

Read MoreDirectMed Parts & Service Announces Partnership and Investment in Technical Prospects

MLCommons Releases New MLPerf Results that Highlight Growing Importance of Generative AI and Storage

Today, MLCommons, the leading open AI engineering consortium, announced new results from two MLPerf™ benchmark suites: MLPerf Inference v3.1, which delivers industry standard Machine Learning (ML) system performance benchmarking in an architecture-neutral, representative, and reproducible manner, and MLPerf Storage v0.5.…

Read MoreMLCommons Releases New MLPerf Results that Highlight Growing Importance of Generative AI and Storage

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95%…

Read MoreExai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron’s Long-Time Chief Financial Officer

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson’s appointment follows the retirement of Olivia Bloom, Geron’s…

Read MoreGeron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron’s Long-Time Chief Financial Officer